Radiomics features and radiomics signature from pretherapeutic 68Ga-PSMA-PET/CT scans as well as patient-specific clinical parameters hold promise for the prediction of overall survival for patients with advanced prostate carcinoma treated with 177Lu-PSMA therapy. Here, FOLH1 is linked to prostate carcinoma.